To Evaluate the Efficacy and Safety of JS002 in HoFH Patients
Status:
Recruiting
Trial end date:
2022-07-29
Target enrollment:
Participant gender:
Summary
JS002 is a recombinant human anti-PCSK9 monoclonal antibody. This phase II open-label,
single-arm study aims to evaluate the efficacy and safety of JS002 in patients with
homozygous familial hypercholesterolemia A dose group (450 mg) was set up in this
study.Thirty subjects are planned to be enrolled.
Each subject required a maximum of 6 weeks of screening, 52 weeks of treatment, and 8 weeks
of follow-up.